Syndax Pharmaceuticals Inc (NAS:SNDX)
$ 13.07 -0.24 (-1.8%) Market Cap: 1.12 Bil Enterprise Value: 710.08 Mil PE Ratio: 0 PB Ratio: 3.04 GF Score: 32/100

Syndax Pharmaceuticals Inc and Incyte Corp Axatilimab Collaboration Call Transcript

Sep 27, 2021 / 12:00PM GMT
Release Date Price: $19.76 (+5.11%)
Operator

Good day, everyone, and welcome to Syndax conference call. Today's call is being recorded. At this time, I would like to turn the call over to Maghan Meyers of Argot Partners. Please begin.

Maghan Meyers

Thank you, operator. Welcome, and thank you to those of you joining us on the line and the webcast this morning for a review of Syndax's announced collaboration with Incyte for the development of axatilimab. I'm Maghan Meyers with Argot Partners, and with me this morning to discuss this collaboration are Dr. Briggs Morrison, Chief Executive Officer; Michael Metzger, President and COO; and Daphne Karydas, Chief Financial Officer. Also joining us on the call today for the question-and-answer session is Dr. Peter Ordentlich, Chief Scientific Officer.

Before we begin, I would like to remind you that any statements made during this call that are not historical, are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these statements as a

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot